Читать книгу Graves' Orbitopathy - Группа авторов - Страница 64
References
Оглавление1 Bartley GB, Fatourechi V, Kardrmas EF, Jacbsen SJ, Ilstrup DM, Garrity JA, Gorman CA: The incidence of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 1995;121:284–290.
2 Abraham-Nordling M, Bystrom K, Torring O, Lantz M, Berg G, Calissendorf J, et al: Incidence of hyperthyroidism in Sweden. Eur J Endocrinol 2011;165:899–905.
3 Laurberg P, Berman DC, Bulow-Pedersen I, Andersen S, Carle A: Incidence and clinical presentation of moderate-to-severe Graves’ orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab 2012;97:2325–2332.
4 Perros P, Hegedüs L, Bartalena L, et al: Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis 2017;12:72.
5 Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrio M, Bartalena L. Prevalence of natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen in a single center. J Clin Endocrinol Metab 2013;98:1443–1449.
6 Perros P, Kendall-Taylor P: Natural history of thyroid eye disease. Thyroid 1998;8:423–425.
7 Weetman AP, Wiersinga WM: Current management of thyroid-associated opthalmopathy in Europe. Results of an international survey. Clin Endocrinol 1998;49:21–28.
8 Perros P, Zarkovic M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, Bernard M, et al: PREGO (Presentation of Graves’ Orbitopathy) study: changes in referral patterns to European Group on Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol 2015;99:1531–1535.
9 Prummel MF, Wiersinga WM: Smoking and risk of Graves’ disease. JAMA 1993;269:479–482.
10 Prummel MF, Bakker A, Wiersinga WM, Baldeschi L, Mourits MP, Kendall-Taylor P, Perros P, Neoh C, Dickinson AJ, Lazarus JH, Lane CM, Heufelder AE, Kahaly GJ, Pitz S, Orgiazzi J, Hullo A, Pinchera A, Marcocci C, Sartini MS, Rocchi R, Nardi M, Krassas GE, Halkias A: Multi-center study on the characteristics and treatment strategies of patients with Graves’ orbitopathy: the first European Group on Graves’ Orbitopathy experience. Eur J Endocrinol 2003;148:491–495.
11 Teller M, Cooper J, Edmonds C: Graves’ ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol 1992;36:291–294.
12 Lim SL, Lim AK, Mumtaz M, Hussein E, Wan Bebakar WM, Khir AS: Prevalence, risk factors, and clinical features of thyroid-associated ophthalmopathy in multiethnic Malaysian patients with Graves’ disease. Thyroid 2008;18:1297–1301.
13 Tsai CC, Kau HC, Kao SC, Hsu WM: Exophthalmos of patients with Graves’ disease in Chinese of Taiwan. Eye 2006;20:569–577.
14 Villanueva R, Inzerillo AM, Tomer Y, Barbesino G, Meltzer M, Concepcion ES, Greenberg DA, Maclaren N, Sun ZS, Zhang DM, Tucci S, Davies TF: Limited genetic susceptibility to severe Graves’ ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Thyroid 2000;10:791–798.
15 Bednarczuk T, Gopinath B, Ploski R, Wall JR: Susceptibility genes in Graves’ ophthalmopathy: searching for a needle in a haystack? Clin Endocrinol 2007;67:3–19.
16 Khalilzadeh O, Anvari M, Esteghamati A, Mahmoudi M, Tahvildari M, Rashidi A, Khosravi F, Amirzargar A: Graves’ ophthalmopathy and gene polymorphisms in interleukin-1alpha, interleukin-1beta, interleukin-1 receptor and interleukin-1 receptor antagonist. Clin Exp Ophthalmol 2009;37:614–619.
17 Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG: Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006;91:3464–3470.
18 Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A: Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992;326:1733–1738.
19 Jackson R, Rosenberg C, Kleinmann R, Vagenakis AG, Braverman LE: Ophthalmopathy after neck irradiation therapy for Hodgkin’s disease. Cancer Treat Rep 1979;63:1393–1395.
20 Khong JJ, Finch S, De Silva C, Rylander S, Craig JE, Selva D, Ebeling PR: Risk factors for Graves’ orbitopathy: the Australian Thyroid-Associated Orbitopathy Research (ATOR) Study. J Clin Endocrinol Metab 2016;7: 2711–2720.
21 Mimura LY, Villares SM, Monteiro ML, Guazzelli IC, Bloise W: Peroxisome proliferator-activated receptor-gamma gene expression in orbital adipose/connective tissues is increased during the active stage of Graves’ ophthalmopathy. Thyroid 2003;13:845–850.
22 Starkey K, Heufelder A, Baker G, Joba W, Evans M, Davies S, Ludgate M: Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use? J Clin Endocrinol Metab 2003;88:55–59.
23 Guo N, Woeller CF, Feldon SE, Phipps RP: Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts. J Biol Chem 2011;286:18856–18867.
24 Trinh T, Haridas AS, Sullivan TJ: Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease. Ophthal Plast Reconstr Surg 2016;32:e128–e129.
25 Chakrabarti S: Thyroid functions and bipolar affective disorder. J Thyroid Res 2011;2011:306367.
26 Byrne AP, Delaney WJ: Regression of thyrotoxic ophthalmopathy following lithium withdrawal. Can J Psychiatry 1993;38:635–637.
27 Villanueva RB, Brau N: Graves’ ophthalmopathy associated with interferon-alpha treatment for hepatitis C. Thyroid 2002;12:737–738.
28 Hägg E, Asplund K: Is endocrine ophthalmopathy related to smoking? Br Med J 1987;295:634–635.
29 Shine B, Fells P, Edwards OM, Weetman AP: Association between Graves’ ophthalmopathy and smoking. Lancet 1990;335:1261–1264.
30 Thornton J, Kelly SP, Harrison RA, Edwards R: Cigarette smoking and thyroid eye disease: a systematic review. Eye 2006;15:1–11.
31 Szurks-Farkas Z, Toth J, Kollar J, Galuska L, Burman KD, Boda J, Leovey A, Varga J, Ujhelyi B, Szabo J, Berta A, Nagy EV: Volume changes in intra- and extraorbital compartments in patients with Graves’ ophthalmopathy: effect of smoking. Thyroid 2005;15:146–152.
32 Bartalena L, Pinchera A, Marcocci C: Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000;21:168–199.
33 Wiersinga WM, Bartalena L: Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 2002;12:855–860.
34 Lim NC, Sunda G, Amrith S, Lee KO: Thyroid eye disease: a Southeast Asian experience. Br J Ophthalmol 2015;99:512–518.
35 Wu Q, Rayman MP, Lv H, et al: Low selenium population status is associated with increased prevalence of thyroid disease. J Clin Endocrinol Metab 2015;100:4037–4047.
36 Jang SY, Lee KH, Oh JR, Kim BY, Yoon JS: Development of thyroid-associated ophthalmopathy in patients who underwent total thyroidectomy. Yonsei Med J 2015;56:1389–1394.
37 Giovansili L, Cayrolle G, Belange G, Clavel G, Herdan ML: Graves’ ophthalmopathy after total thyroidectomy for papillary carcinoma. Ann Endocrinol (Paris) 2011;72:42–44.
Prof. Chantal Daumerie
Service d’Endocrinologie et de Nutrition, Université Catholique de Louvain
Cliniques Universitaires Saint-Luc
Avenue Hippocrate 54, UCL 54.74
BE–1200 Brussels (Belgium)
